Resverlogix Corp (RVXCF)
0.0409
0.00 (0.00%)
USD |
OTCM |
May 06, 16:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 11.23M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -61.42% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | -- |
Price to Book Value | -- |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 98.87% |
Profile
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19. |
URL | https://www.resverlogix.com |
Investor Relations URL | http://www.resverlogix.com/investors/stock_info.html |
HQ State/Province | Alberta |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Growth |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | Nov. 09, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19. |
URL | https://www.resverlogix.com |
Investor Relations URL | http://www.resverlogix.com/investors/stock_info.html |
HQ State/Province | Alberta |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Growth |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | Nov. 09, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |